Stay updated on Adjuvant Pembrolizumab in N2+ NSCLC Clinical Trial

Sign up to get notified when there's something new on the Adjuvant Pembrolizumab in N2+ NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Adjuvant Pembrolizumab in N2+ NSCLC Clinical Trial page

  1. Check
    today
    Change Detected
    Summary
    Revision label updated from v3.4.3 to v3.5.0 at the top of the page. This is a minor version update that does not alter study details.
    Difference
    0.1%
    Check dated 2026-03-25T20:52:09.000Z thumbnail image
  2. Check
    8 days ago
    No Change Detected
  3. Check
    14 days ago
    Change Detected
    Summary
    Revision updated from v3.4.2 to v3.4.3. The visible study content and layout remain unchanged.
    Difference
    0.1%
    Check dated 2026-03-11T17:28:18.000Z thumbnail image
  4. Check
    22 days ago
    Change Detected
    Summary
    A reference to a 2012 NEJM article on PD-L1 was removed from the page’s references.
    Difference
    0.1%
    Check dated 2026-03-04T14:27:33.000Z thumbnail image
  5. Check
    29 days ago
    Change Detected
    Summary
    Deleted the bibliographic reference 'Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372:2018-2028.' from the page. This removal does not alter the study design, endpoints, or other critical trial details.
    Difference
    0.1%
    Check dated 2026-02-25T10:30:26.000Z thumbnail image
  6. Check
    43 days ago
    Change Detected
    Summary
    Revision: v3.4.2 was added and the older funding-status notice (v3.4.1) was removed. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.4%
    Check dated 2026-02-11T04:55:27.000Z thumbnail image
  7. Check
    50 days ago
    Change Detected
    Summary
    Added a site-wide notice about funding status and operations and updated the page version from v3.4.0 to v3.4.1.
    Difference
    0.4%
    Check dated 2026-02-04T04:36:15.000Z thumbnail image

Stay in the know with updates to Adjuvant Pembrolizumab in N2+ NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Adjuvant Pembrolizumab in N2+ NSCLC Clinical Trial page.